Key facts
- Bonum Therapeutics’s last known valuation is $130.0M (Nov 2022).
- It has raised $127.5M across 3 recorded rounds; the latest was Early Stage VC ($26.9M) in Apr 2026.
- Notable investors include Digitalis Ventures, Vivo Capital, American Century Investments, Codon Capital, RiverVest Venture Partners — 6 tracked in total.
- Bonum Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Apr 2026 ($26.9M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Bonum Therapeutics
Funding rounds
3 roundsAbout Bonum Therapeutics
Developer of antibody-based therapeutics designed to enable targeted and regulated treatment of diseases. The company's platform develops protein therapeutics with antibody-controlled activation, engineered sensor domains that trigger activity upon target binding, reversible regulation of function, and cytokine-based approaches for immune response modulation, enabling patients with cancer and other conditions to receive more precise treatments with reduced toxicity and improved therapeutic control.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2021
- Employees
- 33
- Website
- bonumtx.com/
- Ownership
- Privately Held (backing)
Bonum Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bonum Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bonum Therapeutics in its N-PORT filings yet. We sweep new filings monthly.